Article Information
- Received August 6, 2014
- Revision received October 8, 2014
- Accepted October 8, 2014
- First published November 12, 2014.
- Version of record published November 12, 2014.
Author Information
- Lawrence Rajendran1,2,
- Jitin Bali1,2,
- Maureen M. Barr3,
- Felipe A. Court4,5,
- Eva-Maria Krämer-Albers6,
- Frederic Picou4,
- Graça Raposo7,8,
- Kristan E. van der Vos9,
- Guillaume van Niel7,8,
- Juan Wang3, and
- Xandra O. Breakefield10
- 1Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research and
- 2Graduate Schools of Zurich Neuroscience Center and Integrative Physiology, University of Zurich, 8006 Zurich, Switzerland,
- 3Human Genetics Institute, Department of Genetics, Rutgers University, Piscataway, New Jersey 08854,
- 4Millenium Nucleus for Regenerative Biology, Faculty of Biology, Pontificia Universidad Catolica de Chile, Santiago, Chile,
- 5Neurounion Biomedical Foundation, Santiago, Chile,
- 6Department of Molecular Cell Biology, and Focus Programme of Translational Neuroscience, University of Mainz, 55122 Mainz, Germany,
- 7Institut Curie, Centre de Recherche, F-75248 Paris, France,
- 8Structure and Membrane Compartments, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 144, Paris F-75248, France,
- 9Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands, and
- 10Departments of Neurology and Radiology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02114
Author contributions
Disclosures
- Received August 6, 2014.
- Revision received October 8, 2014.
- Accepted October 8, 2014.
L.R. was supported by the Velux Foundation Professorship Grant, the interdisciplinary Swiss National Science Foundation Grant SNF-CR3313-153039, the SCOPES Grant IZ73Z0_152496, the Novartis Foundation Grant, Bangerter Stiftung, and the Synapsis Foundation. M.M.B. and J.W. were supported by National Institutes of Health Grants R01DK059418 and R01DK074746. F.A.C. and F.P. were supported by Grants from Fondo Nacional de Desarrollo Científico y Tecnológico Grants 1110987 and 3130527, Millennium Nucleus RC-120003, and Ring Initiative ACT1109. E.-M.K.-A. was supported by Deutsche Forschungsgemeinschaft research Grants KR 3668/1-1 and DFG SPP1757 (KR-3668/2-1). K.E.v.d.V. was supported by the Dutch Scientific Organisation (NWO-Rubicon). G.v.N. and G.R. were supported by Research Grants from the Amyloidosis Foundation and the Fondation pour la Recherche Medicale. X.O.B. was supported by National Institutes of Health/National Cancer Institute Grants P01 CA069246, CA141150, and U19 CA179563 through the National Institutes of Health Common Fund, the Office of Strategic Coordination/Office of the National Institutes of Health Director. We thank Ms. Suzanne McDavitt for skilled editorial assistance.
The authors declare no competing financial interests.
- Correspondence should be addressed to either of the following: Dr. Xandra O. Breakefield, Molecular Neurogenetics Unit, Massachusetts General Hospital-East, 13th Street, Building 149, Charlestown, MA 02129, breakefield{at}hms.harvard.edu; or Dr. Lawrence Rajendran, Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich, Wagistrasse 12, Schlieren, Switzerland. Rajendran{at}bli.uzh.ch
